财务费用变动幅度为183.96%,原因:借款利息支出增加。 所得税费用变动幅度为47.6%,原因:营业利润增加。 据证券之星公开数据整理，近期恩威医药（301331）发布2025年中报。截至本报告期末，公司营业总收 入4.49亿元，同比上升15.73%，归母净利润3834.42万元，同比上升113.8%。按单季度数据看，第二季 度营业总收入2.53亿元，同比上升23.48%，第二季度归母净利润2203.91万元，同比上升131.73%。本报 告期恩威医药应收账款上升，应收账款同比增幅达48.13%。 本次财报公布的各项数据指标表现尚佳。其中，毛利率49.1%，同比减5.35%，净利率8.54%，同比增 84.74%，销售费用、管理费用、财务费用总计1.72亿元，三费占营收比38.22%，同比减12.2%，每股净 资产10.52元，同比增6.84%，每股经营性现金流0.73元，同比减16.71%，每股收益0.38元，同比增 117.35% | 项目 | 2024年中报 | 2025年中报 | 同比增幅 | | --- | --- | --- | --- | | 营业总收入(元) | 3.88 Z | 4.49 ...

Group 1: Company Performance Overview - The company expects a double-digit revenue growth in 2025, with net profit matching revenue growth levels [3] - In Q1, the incidence of flu and respiratory diseases decreased compared to last year, leading to a slight adjustment in performance due to high base effects [2] - The CHC (Consumer Health Care) business is anticipated to have market opportunities in categories such as cold, skin, gastrointestinal, and orthopedics throughout the year [2] Group 2: CHC Business Development - The CHC business has entered a multi-category development phase, expanding beyond the core three categories to include pediatrics, orthopedics, liver and gallbladder, and gynecology [4] - The company aims to enhance its product line and market share in pediatric cold medications despite facing some pressure [4] - New products like the vitamin D drops are being introduced to support pediatric category growth [4] Group 3: Prescription Drug Strategy - The prescription drug business is developing steadily, with a focus on adapting to policy changes such as centralized procurement [6] - The company aims to increase the proportion of innovative drugs in its prescription drug portfolio [7] - The integration with Tianjin Pharmaceutical is expected to enhance the company's brand influence in the medical sector [7] Group 4: Online Business Growth - The company has seen rapid growth in its online business, targeting a 10% share by 2025 [8] Group 5: Mergers and Acquisitions - The company plans to pursue both internal and external growth strategies, focusing on mergers and acquisitions in strategic emerging industries [9] Group 6: Shareholder Engagement and Dividends - The company has a stable cash dividend ratio of 50% and aims to enhance shareholder satisfaction through its incentive plans [10] Group 7: Future Integration with Tianjin Pharmaceutical - The focus will be on innovation-driven business development in key therapeutic areas, enhancing R&D capabilities, and fostering collaboration between Tianjin Pharmaceutical and the company [12] Group 8: Formula Granules Business Outlook - The formula granules business is expected to achieve recovery growth in 2024 and maintain growth in 2025, despite being affected by policy changes [13]

编号：20250528 恩威医药股份有限公司投资者关系活动记录表 | | 院、诊所）及电商渠道进行销售，公司专门成立了销售二部 | | | | | --- | --- | --- | --- | --- | | | 负责开拓第三终端渠道业务。谢谢! | | | | | | 问题 6：公司大股东增持股份计划目前实施进展如何 | | | | | | 了？ | | | | | | 答：公司控股股东一致行动人成都杰威企业管理有限公 | | | | | | 司股份增持计划目前正在实施之中，公司将敦促成都杰威按 | | | | | | 期完成增持计划并及时履行相关信息披露义务。谢谢! | | | | | 附件清单（如有） | 无 | | | | | 日期 | 日星期三 2025 5 | 年 | 月 | 28 | | | ☑特定对象调研 □分析师会议 | | --- | --- | | 投资者关系活动 | □媒体采访 □业绩说明会 | | 类别 | □新闻发布会 □路演活动 | | | □现场参观 | | | □其他 （请文字说明其他活动内容） | | 参与单位名称及 | 宁银理财 徐厚犇 | | 人员姓名 | 惠升基金 ...